Syncom formulations (India) Limited has formally notified stock exchanges that it does not fall under the "Large Corporate" classification as defined by SEBI regulations. The WHO-GMP and ISO 9001-2000 certified pharmaceutical company submitted this confirmation to both BSE and NSE on April 3, 2026.

Regulatory Compliance Confirmation

The company's confirmation specifically references multiple SEBI circulars that define Large Corporate criteria. The primary regulation cited is SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, which was subsequently updated on April 13, 2022. Additionally, the company referenced SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, along with BSE Notice No. 20220427-2 dated April 27, 2022.

Exemption from Annual Disclosure Requirements

By confirming its non-Large Corporate status, Syncom Formulations is exempt from specific regulatory obligations. The company stated that the requirement for submission of Annual Disclosure in Annexure B2 for the financial year ended March 31, 2026, is not applicable. This exemption represents a significant compliance relief for the company, as Large Corporates face additional disclosure and reporting requirements under SEBI regulations.

Company Profile and Operations

Syncom Formulations operates as a WHO-GMP and ISO 9001-2000 certified pharmaceutical company with CIN No. L24239MH1988PLC047759. The company maintains multiple operational locations across India:

• Registered Office: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai-400 093
• Manufacturing Works: 256-257, Sector-I, Pithampur, Dist.-Dhar, M.P. - 454 775
• Corporate Office: 207, Saket Nagar, Near Saket Club, Indore - 452 018

Stock Exchange Communication

The formal communication was signed by Vaishali Agrawal, Company Secretary and Compliance Officer, and submitted to both major Indian stock exchanges. The company requested that this information be disseminated on BSE and NSE websites for investor awareness. This transparent communication approach demonstrates the company's commitment to regulatory compliance and stakeholder information sharing.

The confirmation ensures that investors and market participants are aware of the company's regulatory status and the corresponding compliance obligations that apply to its operations.

Syncom Formulations (India) Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 on April 7, 2026. Company Secretary and Compliance Officer Vaishali Agrawal digitally signed and submitted the document to both BSE and NSE.

Dematerialization Process Confirmation

The compliance certificate confirms that all securities received from depository participants for dematerialization during Q4FY26 were properly processed. Ankit Consultancy Pvt Ltd, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate.

CS Saurabh Maheshwari, Compliance Officer at Ankit Consultancy Pvt Ltd, certified that:

• All securities received for dematerialization were confirmed to depositories
• Security certificates have been listed on stock exchanges where earlier securities are listed
• Physical certificates were mutilated and cancelled after verification
• Depository names were substituted in the register of members within 15 days

Regulatory Framework

The filing addresses requirements under the current SEBI (Depositories and Participants) Regulation 2018, which replaced the earlier 1996 regulations. This quarterly compliance ensures transparency in the dematerialization process and maintains investor confidence in electronic securities handling.

Distribution and Documentation

Copies of the compliance certificate were sent to key market infrastructure institutions including National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), ensuring comprehensive regulatory compliance across all relevant authorities.